Becton, Dickinson and Company
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas E. Polen
- Full Time Employees
- 72,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1 Becton Drive Franklin Lakes NJ United States 07417-1880
- IPO Date
- Sep 25, 1963
- CIK
- 0000010795
- Website
- bd.com
- Similar Companies
- Business
- Becton, Dickinson and Company (BDX) manufactures and distributes medical devices, instrument systems, and reagents worldwide. The company develops, produces, and sells a broad portfolio of products including syringes, catheters, infusion therapy devices, and diagnostic systems; safety-engineered sharps and vascular access products; BD Alaris infusion pumps and Pyxis medication management solutions; BD FACSAria flow cytometers and Rhapsody single-cell analysis platforms; and laboratory automation systems such as BD Kiestra and BD Synapsys informatics. BD operates in three main segments—BD Medical, BD Life Sciences, and BD Interventional—serving healthcare facilities, laboratories, pharmaceutical companies, and research institutions across North America, Europe, Asia-Pacific, and emerging markets. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD maintains a global presence with manufacturing facilities in more than 50 countries. In recent developments, BD completed the spin-off of its Biosciences solution business into a standalone entity in early 2025, enabling focused growth in high-margin diagnostics and cell analysis; the company also expanded its partnership with GE HealthCare for integrated medication management technologies and launched new Alaris iPC infusion pump features to enhance cybersecurity and interoperability.
Company News
BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
BD Names Bridget Bagnato Worldwide President of Peripheral Intervention
BDX Gears Up to Report Q4 Results: How to Play the Stock?
Becton Dickinson (BDX) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment
Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November
Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
American Century Equity Income Fund Q3 2026 Portfolio Activity
Best Dividend Aristocrats For November 2026
BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
Citizens Financial Group Inc. RI Purchases 4,390 Shares of Becton, Dickinson and Company $BDX
First Eagle Global Fund Q3 202 Portfolio Update
First Eagle U.S. Value Fund Q3 2026 Portfolio Review
Best Dividend Kings: October 2026
The Dividend Aristocrats Ranked By Quality Scores (October 2026)
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
3,815 Becton, Dickinson and Company $BDX Shares Bought by CFS Investment Advisory Services LLC
Becton, Dickinson and Company $BDX Position Trimmed by Louisbourg Investments Inc.
Becton, Dickinson and Company $BDX Stock Sold by Forbes J M & Co. LLP